Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

300
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
300
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

357
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
357
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

259
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
259
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mucus Plug Formation is Associated with Eosinophilic Activation in Chronic Obstructive Pulmonary Disease.

American journal of respiratory and critical care medicine·2026
Same author

Airway Mucus Plugs in Asthma and COPD: Pathobiology, Imaging, and Implications for Clinical Trials.

American journal of respiratory and critical care medicine·2026
Same author

Every Exacerbation Counts: Shifting the Dial for Future Exacerbation Risk.

American journal of respiratory and critical care medicine·2026
Same author

Small airways obstruction predicts cardiovascular disease incidence: a longitudinal study of UK Biobank.

ERJ open research·2026
Same author

A Brief History of COPD: As Told by Some of Its Senior Scientists and Clinicians.

Journal of clinical medicine·2026
Same author

Inhaler Technique in Chronic Obstructive Pulmonary Disease: Patient Impairments and Bronchodilation.

Annals of the American Thoracic Society·2026
Same journal

When an Exacerbation Signals a Different Future in non-severe asthma.

American journal of respiratory and critical care medicine·2026
Same journal

Aim High-Stay Stable: Rethinking Treatment Success in COPD.

American journal of respiratory and critical care medicine·2026
Same journal

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

American journal of respiratory and critical care medicine·2026
Same journal

Signal in the Noise: Polygenic Scores and the Problem of Defining Idiopathic Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2026
Same journal

Do mtDNA fragmentomic peaks reflect cancer biology or preanalytical and technical artifacts in NSCLC?

American journal of respiratory and critical care medicine·2026
Same journal

Short for Their Age: Interpreting Whole-Genome Telomere Length in Idiopathic Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.1K

Minimal clinically important differences in pharmacological trials.

Paul W Jones1, Kai M Beeh, Kenneth R Chapman

  • 11 Division of Clinical Science, St George's University of London, London, United Kingdom.

American Journal of Respiratory and Critical Care Medicine
|January 4, 2014
PubMed
Summary
This summary is machine-generated.

The minimal clinically important difference (MCID) provides benchmarks for treatment success in chronic obstructive pulmonary disease (COPD). While validated MCIDs exist for lung function, dyspnea, health status, and exercise capacity, none are established for exacerbations.

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

2.0K

Related Experiment Videos

Last Updated: May 4, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.1K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

2.0K

Area of Science:

  • Pulmonary Medicine
  • Clinical Trial Design
  • Health Outcomes Research

Background:

  • The minimal clinically important difference (MCID) is crucial for interpreting treatment effects in clinical practice and research.
  • MCIDs represent the smallest change in an outcome that patients perceive as beneficial.
  • Understanding MCIDs is essential for evaluating the clinical relevance of therapeutic interventions.

Purpose of the Study:

  • To review the evidence and methodologies for defining MCIDs in chronic obstructive pulmonary disease (COPD).
  • To identify validated MCIDs for commonly used outcomes in COPD.
  • To discuss the application and challenges of MCIDs in clinical trials, particularly those comparing active treatments.

Main Methods:

  • Systematic review of existing literature on MCID determination in COPD.
  • Analysis of empirically derived MCID estimates for various COPD outcome measures.
  • Discussion of factors influencing MCID achievement in clinical trials.

Main Results:

  • Validated MCIDs are available for lung function (FEV1), dyspnea (TDI, SOQ), health status (SGRQ), and exercise capacity (ISWT, SWTT, cycling tests).
  • No validated MCID currently exists for COPD exacerbations.
  • Factors such as study duration, withdrawal rates, and baseline severity impact treatment effects relative to MCID.

Conclusions:

  • MCIDs are valuable for assessing the clinical significance of treatment effects in COPD.
  • The concept of 'minimum worthwhile incremental advantage' is proposed for trials comparing active treatments.
  • Further research is needed to establish MCIDs for COPD exacerbations and refine their application in comparative trials.